Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Myeloproliferative Disorders 3Lymphoma 3Primary Myelofibrosis 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 45Cyclophosphamide 32Lenalidomide 24fludarabine 20zanubrutinib 13venetoclax 12obinutuzumab 12orelabrutinib 11fludarabine phosphate 10Bendamustine Hydrochloride 10Magnetic Resonance Spectroscopy 9Whole-Body Irradiation 8Prednisone 8pirtobrutinib 7ibrutinib 7Vincristine 7Specimen Handling 7CT-P10 7Mycophenolic Acid 6Biopsy 6Doxorubicin 5tafasitamab 4pembrolizumab 3acalabrutinib 3Tacrolimus 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × parsaclisib × 1 year × Clear all
NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Incyte Corporation

Phase 1 Completed
50 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Incyte Corporation

Phase 2 Completed
110 enrolled 18 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡